Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas

Histopathology

Volumn 68, Issue 7, 2016, Pages 1079-1089

  Kwon, Dohee ^a   Kim, Sehui ^a   Kim, Pil Jong ^b   Go, Heounjeong ^c   Nam, Soo Jeong ^d,e   Paik, Jin Ho ^f   Kim, Young A ^g   Kim, Tae Min ^a   Heo, Dae Seog ^a   Kim, Chul Woo ^a,e,h   Jeon, Yoon Kyung ^a,e,h  

^a Seoul National University Hospital   (South Korea)

^b BK 21 Plus   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Korea Cancer Center Hospital   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

^g Seoul National University Boramae Hospital   (South Korea)

^h Seoul National University   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Immunotherapy; Programmed cell death 1; Programmed cell death 1 ligand 1; Tumour associated macrophages

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; VINCRISTINE; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INFILTRATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ADOLESCENT; AGED; CHILD; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84964797263     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12882     Document Type: Article

References (35)

1. Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008.
2. Schneider C, Pasqualucci L, Dalla-Favra R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin. Diagn. Pathol. 2011; 28; 167-177.
3. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2011; 201; 498-505.
4. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008; 26; 677-704.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012; 12; 252-264.
6. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 2007; 19; 813-824.
7. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 2012; 24; 207-212.
8. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012; 366; 2455-2465.
9. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012; 366; 2443-2454.
10. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015; 372; 311-319.
11. Westin JR, Chu F, Zhang M et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014; 15; 69-77.
12. Armand P, Nagler A, Weller EA et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 2013; 31; 4199-4206.
13. Krishnan C, Warnke RA, Arber DA, Natkunam Y. PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. Am. J. Surg. Pathol. 2010; 34; 178-189.
14. Xerri L, Chetaille B, Serriari N et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum. Pathol. 2008; 39; 1050-1058.
15. Chen BJ, Chapuy B, Ouyang J et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 2013; 19; 3462-3473.
16. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res. 2011; 17; 4232-4244.
17. Wilcox RA, Feldman AL, Wada DA et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009; 114; 2149-2158.
18. Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116; 3268-3277.
19. Twa DD, Chan FC, Ben-Neriah S et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014; 123; 2062-2065.
20. Wilcox RA, Ansell SM, Lim MS, Zou W, Chen L. The B7 homologues and their receptors in hematologic malignancies. Eur. J. Haematol. 2012; 88; 465-475.
21. Green MR, Rodig S, Juszczynski P et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 2012; 18; 1611-1618.
22. Myklebust JH, Irish JM, Brody J et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 2013; 121; 1367-1376.
23. Carreras J, Lopez-Guillermo A, Roncador G et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J. Clin. Oncol. 2009; 27; 1470-1476.
24. Richendollar BG, Pohlman B, Elson P, Hsi ED. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum. Pathol. 2011; 42; 552-557.
25. Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1 + tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum. Pathol. 2009; 40; 1715-1722.
26. Ahearne MJ, Bhuller K, Hew R, Ibrahim H, Naresh K, Wagner SD. Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma. Virchows Arch. 2014; 465; 351-358.
27. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009; 15; 5494-5502.
28. Nam SJ, Go H, Paik JH et al. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk. Lymphoma 2014; 55; 2466-2476.
29. Kundel HL, Polansky M. Measurement of observer agreement. Radiology 2003; 228; 303-308.
30. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014; 20; 5064-5074.
31. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515; 563-567.
32. Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2014; 20; 256-261.
33. Fang W, Zhang J, Hong S et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget 2014; 5; 12189-12202.
34. Park S, Lee J, Ko YH et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 10; 972-978.
35. Rossille D, Gressier M, Damotte D et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014; 28; 2367-2375.